The 4th Cytokine-Based Drug Development Summit united a unique group of 80+ C-level, VP and Director key decision makers from within the Cytokine community.
For our audience to be able to meet their research objectives they required the support of accurate and expert service providers with specialism in cytokine studies.
The requirement for providers of preclinical services ranging from in vitro MoA studies through to in vivo GLP toxicity studies with expertise has never been more timely.
As the only industry meeting solely focused on developing cytokine-based drugs with a widened therapeutics index and overcoming translational challenges during development, this summit presented the perfect platform to showcase your solutions to our targeted audience of experts at the forefront of cytokine-based drug development.
Partners enhanced their visibility through bespoke partnership packages and took advantage of the valuable networking opportunities on offer, allowing them to hold important conversations to mature existing relationships and establish new clients with those who are eager to propel the development of their cytokine-based drugs.
Get in touch today to learn about how we can support your commercial objectives within this space in 2024.